The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

Join Dr. Raymond A. Huml, Vice President of Rare Strategy, Sciensus; Andrew Cummins, Vice President of Business Development, Sciensus; and Kirsty Hoyle, CEO, Metabolic Support UK, for the live webinar ...

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug ...

UK-based public health agency, Knowledge?Action?Change (K?A?C), is launching a free online course called Understanding ...

In today’s evolving pharmaceutical environment, the fill‐finish segment stands out as a critical linchpin connecting drug ...

Sigrid Therapeutics (Sigrid) is excited to announce that it has secured U.S. market access for its proprietary SiPore� technology, following the success of the SHINE study, the largest of its kind in ...

The TSXV serves as a vital platform for early-stage, high-growth companies, providing access to capital and a strong investor network. In 2024, 80% of the TSXV Venture 50™ companies operated ...

The department had last week sought expressions of interest from interested entities for project funding under the PRIP ...

Montpellier, France Monday, March 10, 2025, 15:00 Hrs [IST] ...

We recently published a list of 12 Stocks with Heavy Insider Buying in 2025. In this article, we are going to take a look at ...

Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...